BioSpace News Archive

The report provides a detailed analysis of changing market dynamics, top segments, value chain, key investment pockets, regional scenario, and competitive landscape.

Rise in awareness regarding early diagnosis of disease, prevalence of infectious diseases, and need for low cost as well as accurate diagnostic testing drive the growth of the global rapid tests market.

Increasing geriatric population, rising use of regional anesthesia, and increasing volume of surgical procedures across the globe are major factors driving market revenue growth.

Rise in geriatric population, increase in number of biochip applications, and high adoption of personalized medications is driving biochip market revenue growth.

Rising awareness regarding effectiveness of knee replacement implants products and high obesity rate are factors driving knee replacement implants market revenue growth.

Technological advancements in molecular testing techniques and increasing prevalence of different types of cancer and neurological disorders are key factors fueling global market revenue growth.

Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, Jaguar’s president, founder, and CEO, will present at NobleCon18 - Noble Capital Markets’ Eighteenth Annual Investor Conference at the Hard Rock Hotel & Casino in Hollywood, Florida on Thursday, April 21, 2022, at 11:00 AM Eastern.

Global life sciences software company IDBS announces the latest release of its Skyland PIMS® software, which seamlessly combines product, process, and patient data across the biopharma life cycle and supply chain, providing insights that accelerate process understanding and ensure product quality.

MaxHealth, a Florida based organization, focused on providing patient-centered healthcare primarily to Medicare-eligible patients, announces the appointment of Prakash Patel, M.D., as Chief Executive Officer.

On April 1, Dragon Boat Pharmaceutical announced that its self-developed anti-CLDN18.2 antibody injection (BC008) had obtained the implied approval for clinical trials from China’s National Medical Products Administration, and will be used for the clinical trials in the treatment of CLDN18.2-positive advanced malignant solid tumors.